Skip to main content
  • EN
  • FI
  • SV
Login

Main navigation

  • About FinnGen
    • Summary & Goals
      • Goals
      • FinnGen 1-2
      • FinnGen 3 (2023-2027)
    • Consortium
      • Partners
      • Funding
      • Governance
      • Steering Committee Members
      • Scientific Committee Members
      • Teams
      • Collaboration
    • Impact
      • National Impact
      • National Research Network
      • Open Science
      • Research Highlights
    • Why Finland?
      • Biobank Network
      • Legislative Review
      • National Registries
      • Population Genetic History
      • Industry partners
    • Mediabank
  • For Researchers
    • Research Activities
      • Core Analyses
      • Disease Task Forces
      • Expansion Areas
      • Global Initiatives
    • Cohort and Data
      • Register Data
      • Basic Characteristics
      • Clinical Endpoints
      • Genetic Data
      • Laboratory Values
      • Other Phenotype Data
      • Recruitment
      • Other Biological Data
      • Data Available
    • Accessing Data, Results & Tools
      • Access results
      • Computing environment
      • How we collaborate
      • Partner researchers
      • Public data releases
      • Tools
    • Publications
    • Researcher FAQ
  • For Participants
    • Participation
      • Study Participants
      • Biobanks' Role in FinnGen
      • Biobank Contact Information
      • Recall Studies
      • Questions and answers
    • Data Protection and Security
      • Data Protection
      • Data Security
      • Sample & Data Flow
      • Data Protection Statement
    • Significance
      • Videos
  • News
  • EN
  • FI
  • SV

Links

  • PheWeb
  • Risteys
  • Meta-analysis Pheweb (FG-MVP-UKBB)
  • FinnGen handbook
  • Meta-analysis Pheweb (FG-UKBB)
  • Coding variant browser
  • Endpoint Browser
  • FinnGen GITHUB
  • LAVAA volcano plot
  • Multiple Manhattan Plot
  • Variant Cluster Corrector
  • Variant Cluster Call Corrector
Breadcrumb
  1. Home

Large-scale evaluation of proteomic and polygenic risk scores reveals complementary contributions to incident disease prediction

Submitted by Frida Mäkelä on Tue, 07/15/2025 - 11:14
  • Read more about Large-scale evaluation of proteomic and polygenic risk scores reveals complementary contributions to incident disease prediction

Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for osteomyelitis

Submitted by Frida Mäkelä on Tue, 07/15/2025 - 10:56
  • Read more about Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for osteomyelitis

PARK7 is a Key Regulator of Oxidative Stress - Related Breast Cancer Risk: A Multi-Omics Study

Submitted by Frida Mäkelä on Tue, 07/15/2025 - 09:53
  • Read more about PARK7 is a Key Regulator of Oxidative Stress - Related Breast Cancer Risk: A Multi-Omics Study

Genetic Association Between Sleep Traits and Vertigo Risk: A Two-Sample Bidirectional Mendelian Randomization Study

Submitted by Frida Mäkelä on Tue, 07/15/2025 - 09:49
  • Read more about Genetic Association Between Sleep Traits and Vertigo Risk: A Two-Sample Bidirectional Mendelian Randomization Study

Unveiling the interplay among skin microbiota, cytokines, and T2DM: an insightful Mendelian randomization study

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 16:35
  • Read more about Unveiling the interplay among skin microbiota, cytokines, and T2DM: an insightful Mendelian randomization study

The genetics of low and high birthweight and their relationship with cardiometabolic disease

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 16:28
  • Read more about The genetics of low and high birthweight and their relationship with cardiometabolic disease

Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:53
  • Read more about Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study

Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:44
  • Read more about Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization

Uncovering leading compounds for alzheimer’s disease treatment: mendelian randomization and virtual screening insights into plasma protein modulation

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:40
  • Read more about Uncovering leading compounds for alzheimer’s disease treatment: mendelian randomization and virtual screening insights into plasma protein modulation

Warfarin use and vestibular dysfunction insights from NHANES data, network pharmacology, Mendelian randomization, and molecular docking

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:34
  • Read more about Warfarin use and vestibular dysfunction insights from NHANES data, network pharmacology, Mendelian randomization, and molecular docking

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 164
  • Page 165
  • Page 166
  • Page 167
  • Current page 168
  • Page 169
  • Page 170
  • Page 171
  • Page 172
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Contact us

Contact person
finngen-info@helsinki.fi
Follow us on Bluesky
@finngen.bsky.social
Follow us on LinkedIn
https://www.linkedin.com/company/finngen/

Lead organisations

The University of Helsinki is the organization responsible for the FinnGen research project. The Finnish consortium partners include all Finnish public biobanks and their background organisations, so the project covers the whole of Finland. All partners are listed on this page.

About the website

Accessibility statement